Malignant jaundice refers to obstructive and progressive aggravated jaundice caused by malignant tumors (such as cholangiocarcinoma, pancreatic head cancer, hepatocellular carcinoma, etc.). Due to the insidious early symptoms and low early diagnosis rate, once jaundice seen by the naked eye appears, most patients have lost the opportunity for radical surgery, and if surgical treatment measures are not taken, most patients will die from various complications caused by jaundice, such as cholangitis (chills and fever), liver function failure, cachexia, etc. Therefore, improving the quality of life of such patients in the late stage becomes a primary consideration. Since its application in biliary surgery in the 1960s, the effect of percutaneous hepatic puncture and drainage (PTCD) in malignant jaundice has been well established and has become an effective, minimally invasive treatment for patients with inoperable malignant jaundice in advanced stages. After 1 week, the bilirubin indexes of the patients all dropped by more than 1/4 of the original level, and the patients recovered smoothly after the operation, and the jaundice had disappeared in 7 patients at follow-up. With the development of PTCD, the quality of life of these patients with malignant jaundice will definitely be improved in the late stage.